Targacept shares tank on mid-stage pain failure

Shares of Targacept swiftly plunged 20 percent this morning after reporting that an experimental pain therapy--TC-2696--failed a mid-stage study and may not be a viable therapy for treating post-surgery pain. Researchers failed to find statistically significant pain relief four to six hours following surgery, compared to a placebo effect. Targacept plans to analyze the data and talk it over with its partner, GlaxoSmithKline.

- check out this release
- here's the AP report for more

Related Articles:
Targacept pushes depression therapy into the clinic. Report
Targacept raises IPO cash. Report
Targacept takes second shot at $60M IPO. Report
Targacept gains $20M payment from AstraZeneca. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.